Abstract
Ultrasound energy for thrombolysis dates back to 1976. Trubestein et al. demonstrated first in vitro that a rigid wire delivery low frequency ultrasound energy could disrupt clot. These investigators also showed that this system had potential for peripheral arterial clot dissolution in vivo in animal studies [G. Trubestein, C. Engel, F. Etzel, Clinical Science 51 (1976) 697s–698s]. Subsequently, four basic approaches to ultrasonic thrombolysis have been pursued – two without pharmacological agents: (1) catheter-delivered external transducer ultrasound, (2) transcutaneous-delivered HIFU external ultrasound without drug delivery and ultrasound in conjunction with thrombolytic drugs and/or microbubbles or other agents, (3) Catheter-delivered transducer-tipped ultrasound with local drug delivery, and (4) transcutaneous-delivered low frequency ultrasound with concomitant systemic (intravenous) drug delivery for site specific ultrasound augmentation. This article reviews recent data on therapeutic ultrasound for thrombolysis in vitro, in vivo, in animal studies, as well as in human clinical trials.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
